Vladislavs Sokalskis

Dr. Vladislavs Sokalskis


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
VSVladislavs Sokalskis
Vladislavs Sokalskis
KKKaspars Kupics
Kaspars Kupics
KJKristaps Jurjāns
Kristaps Jurjāns
NŅNikolajs Ņesterovičs
Nikolajs Ņesterovičs
IOIeva Ozoliņa
Ieva Ozoliņa
AĒAndrejs Ērglis
Andrejs Ērglis
Background and aims: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CES). Non-adherence to direct oral anticoagulants (DOACs) remains a major health policy issue. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Methods: This retrospective study analyzed data on DOAC usage from CES patients with AF admitted to the two largest Latvian university hospitals between January 2022 and December 2024. We further compared patients’ characteristics receiving prior DOAC therapy and those who were not, confirming our findings by a propensity-matched analysis of both groups. Results: Of the 2,610 CES patients enrolled, the largest subgroup (43.4%) consisted of individuals with known AF who were not on anticoagulation therapy before the stroke event. A propensity-matched analysis adjusted for demographics, arrival time, AF type, HAS-BLED, and CHA 2 DS 2 -VA score (352 patients per group) revealed that patients taking DOACs presented with significantly milder strokes than non-users (mean admission NIHSS score: 8.84 ± 6.76 vs. 11.58 ± 6.98, p < 0.001). Stroke patients on DOAC therapy demonstrated significantly larger left atrial volume indices (LAVI) than non-users (56.05 ± 19.31 vs. 46.94 ± 14.33, respectively; p < 0.001). Conclusion: Non-adherence to DOACs is a substantial contributor to the CES burden. Prior DOAC use is associated with significantly reduced initial stroke severity. Patients with CES while on DOACs exhibited substantially larger left atria.

27 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VSVladislavs Sokalskis
Vladislavs Sokalskis
Kaspars KupicsKaspars Kupics
Kaspars Kupics
KJKristaps Jurjāns
Kristaps Jurjāns
IOIeva Ozoliņa
Ieva Ozoliņa
GKGuntis Karelis
Guntis Karelis
AEAndrejs Erglis
Andrejs Erglis
Background and Objectives: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CS). AF-related mortality increased substantially in Eastern Europe in the last decade. While direct oral anticoagulants (DOACs) are effective for stroke prevention, non-adherence is a major clinical problem. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Materials and Methods: This retrospective study analysed data from CS patients with AF admitted to the two largest Latvian university hospitals from January 2022 to December 2024. Secondly, a propensity-matched analysis was performed on a single-centre cohort to compare outcomes between patients receiving DOAC therapy and those not. Results: Of 2773 patients enrolled, the largest subgroup (45%) consisted of patients with known AF who were not on appropriate anticoagulation therapy before the stroke event. The propensity-matched analysis based on demographics, arrival time, AF type, and CHA 2 DS 2 -VA score (163 patients per group) revealed that patients taking DOACs presented with significantly milder strokes than non-users (mean admission NIHSS: 9.8 vs. 11.6, p=0.009). 40.5% of DOAC users received a reduced DOAC dose, and in 22.1% the DOAC dose was reduced inadequately. Stroke patients on DOAC therapy had significantly larger left atrial volume indices (LAVI) than non-users (56.4 vs. 48.0, respectively; p=0.004). Conclusions: Non-adherence to DOACs represents a substantial contributor to the CS burden. Prior DOAC use is associated with significantly reduced initial stroke severity, highlighting the protective benefit of therapy even when it fails to prevent an event.